![](https://investorshub.advfn.com/uicon/61569.png?cb=1621345219)
Tuesday, June 07, 2022 4:09:22 PM
Howard Kim
May 20, 2022,
In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Inhibikase Therapeutics (IKT – Research Report), with a price target of $6.00. The company’s shares closed last Friday at $0.63, close to its 52-week low of $0.62.
According to TipRanks.com, Roy is a 3-star analyst with an average return of 3.7% and a 29.7% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Actinium Pharmaceuticals.
Currently, the analyst consensus on Inhibikase Therapeutics is a Moderate Buy with an average price target of $6.00.
Successful Trading is the art of minimizing long term risk and maximizing capital allocation.
Recent IKT News
- Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity • GlobeNewswire Inc. • 08/14/2024 08:25:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:14:00 PM
- Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024 • GlobeNewswire Inc. • 08/07/2024 12:00:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/18/2024 09:23:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/18/2024 09:18:33 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 06/18/2024 09:27:36 PM
- Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease • GlobeNewswire Inc. • 06/17/2024 12:05:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 06/10/2024 08:20:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:05:30 PM
- Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs • GlobeNewswire Inc. • 06/05/2024 12:05:00 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 06/04/2024 08:11:31 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/22/2024 12:55:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 12:55:02 PM
- Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million • GlobeNewswire Inc. • 05/20/2024 12:01:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/20/2024 11:09:42 AM
- Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity • GlobeNewswire Inc. • 05/16/2024 12:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 09:04:56 PM
- Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement • GlobeNewswire Inc. • 05/15/2024 12:45:00 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 05/15/2024 11:56:55 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/09/2024 06:41:37 PM
- Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension • GlobeNewswire Inc. • 05/09/2024 12:00:00 PM
- Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs • GlobeNewswire Inc. • 04/18/2024 08:30:00 PM
- Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension • GlobeNewswire Inc. • 04/03/2024 12:05:00 PM
- Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity • GlobeNewswire Inc. • 03/27/2024 08:15:20 PM
- Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders • GlobeNewswire Inc. • 03/07/2024 01:30:00 PM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM